Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Short term Debt (2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Short term Debt for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt changed N/A to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a N/A change, with the full-year FY2025 number at $4.6 million, changed N/A from a year prior.
  • Short term Debt was $4.6 million for Q4 2025 at Lexicon Pharmaceuticals, down from $42.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $42.1 million in Q1 2025 to a low of $4.6 million in Q4 2025.